Author(s)

Peter K. Law, Lei Ye, Husnain Kh. Haider, Ping Lu, Danlin M. Law, Eugene K. W. Sim

Cell Therapy Institute, Wuhan, China.
Department of Medicine, University of Minnesota, Minnesota, USA;.
Department of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Cincinnati, USA;.
Gleneagles JPMC Cardiac Center, Brunei Darussalam.

This article reviews the scientific development of angiomyogenesis using VEGF₁₆₅-myoblasts, a patented biotechnology platform in regenerative medicine associated with Human Myoblast Genome Therapy (HMGT), also known as Myoblast Transfer Therapy (MTT). VEGF₁₆₅-myoblasts are the leading biologics for angiomyogenesis. This review also compares the safety and efficacy of VEGF₁₆₅-myoblasts transduced using adenoviral vectors, nanoparticles or liposomes, in anticipation of their application in clinical trials in the near future. VEGF₁₆₅-myoblasts are differentiated myogenic cells capable of extensive division, natural cell fusion, nucleus transfer, cell therapy and genome therapy. Following transplantation they survive, develop and function to revitalize degenerative myocardium in heart failure and ischemic cardiomyopathy animal studies. VEGF₁₆₅-myoblasts are second generation products of HMGT/MTT which replenishes live cells and genetically repairs degenerating myofibers in Type II diabetes, muscular dystrophies, aging dysfunction and disfigurement. Myoblasts have also been used to enhance skin and muscle appearance in cosmetology. We envision that VEGF₁₆₅-myoblasts will provide better outcome than their non-tranduced counterparts. Myoblasts are not stem cells. Their competitive advantages over stem cells are presented.

Angiomyogenesis; Cell Therapy; Gene Therapy; VEGF₁₆₅-Myoblasts; Muscular Dystrophies; Heart Failure; Ischemic Cardiomyopathy; Type II diabetes; Anti-Aging Cosmetics; Sexual Impotency;Baldness; Stem Cells

Law, P., Ye, L., Haider, H., Lu, P., Law, D. and Sim, E. (2012) Therapeutic angiomyogenesis using human non-viral transduced VEGF₁₆₅-myoblasts. Open Journal of Regenerative Medicine, 1, 1-9. doi: 10.4236/ojrm.2012.11001.